肌少症对上皮性卵巢癌铂紫杉醇化疗生存与毒性的预测作用
本研究回顾性纳入2000年6月至2017年2月接受铂类和紫杉醇类一线化疗的上皮性卵巢癌患者201例,通过CT评估第三腰椎骨骼肌面积定义肌少症(SMI≤41)。
要点
- 肌少症与总生存无显著差异(36.5 vs 40.8个月,p=0.4)。
- 肌少症未增加化疗剂量调整、住院或毒性反应。
核心结论
- 在本队列中,肌少症与接受一线铂类和紫杉醇类化疗的上皮性卵巢癌患者更差的生存结局或化疗毒性无关。
研究设计与样本
- 回顾性队列研究,纳入2000年6月至2017年2月诊断并接受铂类和紫杉醇类化疗的上皮性卵巢癌患者201例。
- 通过CT腹部图像评估第三腰椎骨骼肌面积,使用TomoVision®软件测量,肌少症定义为骨骼肌指数(SMI)≤41。
主要发现
- SMI>41与SMI≤41患者的总生存均值分别为36.5个月和40.8个月,差异无统计学意义(p=0.4)。
- 两组在剂量减少、剂量延迟、住院、方案变更、输血或毒性反应频率上均无差异。
- 毒性分级分布无差异。
关键数值与推荐
- 肌少症定义:骨骼肌指数(SMI)≤41。
- 总生存均值:SMI>41组36.5个月,SMI≤41组40.8个月,p=0.4。
临床怎么用
- 对于接受铂类和紫杉醇类化疗的上皮性卵巢癌患者,诊断时肌少症可能不应作为预测生存或化疗毒性的独立依据。
- 未来需前瞻性研究探索预防或逆转肌少症的干预措施,以期改善卵巢癌生存、体能状态和生活质量。
局限性
- 本研究为回顾性研究,样本量201例,可能存在选择偏倚。
- 肌少症仅基于CT第三腰椎骨骼肌面积评估,未考虑其他肌肉功能指标。
- 未报告其他潜在混杂因素(如年龄、分期、手术状态等)的调整分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe skeletal muscle loss (sarcopenia) is associated with poor cancer outcomes, including reduced survival and increased treatment toxicity. Our goal was to evaluate if sarcopenia was associated with worse survival outcomes and chemotoxicity in EOC patients undergoing primary platinum and taxane-based chemotherapy. METHODS: EOC patients diagnosed between 06/2000 and 02/2017 who received treatment with platinum and taxane-based chemotherapy were included. CT abdominal images closest to the time of diagnosis were retrospectively evaluated for skeletal muscle area at the 3rd lumbar vertebrae. Measurements were obtained with use of TomoVision® radiological software (SliceOmatic - version 5.0, Quebec, Canada). Sarcopenia was defined as Skeletal Muscle Index (SMI) ≤ 41. Data analysis included Kaplan-Meier plots to assess survival, and unpaired t-tests were used to compare the means by groups. RESULTS: 201 EOC patients were evaluated. Sixty-four percent (128/201) met criteria for sarcopenia (SMI ≤ 41) at time of diagnosis. The mean overall survival did not differ between patients with SMI > 41 and SMI ≤ 41 (36.5 vs 40.8 months, p = 0.4, respectively). No difference in frequency of dose reduction, dose delay, hospital admissions, changes in regimen, blood transfusion, or toxicity was noted. There was no difference in distribution of toxicity grade. CONCLUSION: Sarcopenia was not associated with worse survival outcomes or chemotoxcity in EOC patients receiving first-line platinum and taxane-based chemotherapy in this cohort. Future prospective studies should focus on interventions to prevent or reverse sarcopenia and possibly increase ovarian cancer survival, performance status, and quality of life.
引用
- Staley SA, Tucker K, Newton M, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020. PMID: 31928805. doi:10.1016/j.ygyno.2020.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。